Skip to main content

Recombinant Human Octa-Ub/Ub8 WT Chains (K63-linked), CF

R&D Systems, part of Bio-Techne | Catalog # UC-318B

R&D Systems, part of Bio-Techne
Discontinued Product
UC-318B has been discontinued. View all Octa-Ubiquitin products.

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Bioactivity, Enzyme Activity

Product Specifications

Source

E. coli-derived human Octa-Ubiquitin protein

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.

Predicted Molecular Mass

68 kDa

Activity

Ubiquitin chains vary in length, linkage, and function. K63-linked Octa-Ubiquitin Chains (Ub8) are ideal for investigating Ubiquitin-binding proteins and as substrates for Ubiquitin-specific isopeptidases. Reaction conditions will need to be optimized for each specific application. IMPORTANT: Heating this product in SDS-PAGE buffer or terminating reactions containing this product with heated SDS-PAGE buffer could lead to unexpected, high apparent molecular weight banding or smearing on gels that is not representative of product purity. For optimal results, we recommend incubation in SDS-PAGE buffer + DTT at <40 °C for 20 minutes prior to gel electrophoresis.

None

Formulation, Preparation and Storage

UC-318B
Formulation 1 mg/ml (15 μM) in sterile, deionized water
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: Octa-Ubiquitin

With a predicted molecular weight of 68 kDa, octa-Ubiquitin chains are composed of eight Ubiquitin monomers, which are covalently linked through isopeptide bonds that typically form between a lysine residue of one Ubiquitin molecule and the C-terminal glycine residue of another Ubiquitin molecule (1). Each human Ubiquitin monomer is 76 amino acids (aa) in length and shares 96% and 100% aa identity with yeast and mouse Ubiquitin, respectively (2). Seven of the 76 aa in Ubiquitin are lysine residues that can participate in poly-Ubiquitin chain formation. Linkage through each of the lysine residues is thought to serve as a signal that affects protein degradation, signaling, trafficking, and other cellular processes (3-8).

Linkage specific octa-Ub can be used to investigate mechanism of binding and recognition by E1 or E2 enzymes, deubiquitinating enzymes, E3 ligases, the proteasome or other proteins that contain Ubiquitin-associated domains (UBAs) or Ubiquitin-interacting motifs (UIMs). This product is formed with wild-type Ubiquitin and linkage-specific enzymes. It has been shown that the rate of Ubiquitin-substrate conjugate degradation is related to poly-Ubiquitin chain length. Tetra-Ubiquitin is the minimal unit required for recognition by the proteasome, and longer chains probably have enhanced binding to proteasomal subunits and may be more resistant to disassembly by a proteasome-associated isopeptidases.

References

  1. Scheffner, M. et al. (1995) Nature 373:81.
  2. Sharp, P.M. & W.-H. Li (1987) Trends Ecol. Evol. 2:328.
  3. Behrends, C. & J.W. Harper (2011) Nat. Struct. Mol. Biol. 18:520.
  4. Greene, W. et al. (2012) PLoS Pathog. 8:e1002703.
  5. Henry, A.G. et al. (2012) Dev. Cell 23:519.
  6. Tong, X. et al. (2012) J. Biol. Chem. 287:25280.
  7. Wei, W. et al. (2004) Nature 428:194.
  8. Zhang, J. et al. (2012) J. Biol. Chem. 287:28646.

Alternate Names

OctaUbiquitin, Ub8

Entrez Gene IDs

7314 (Human)

Gene Symbol

UBB

UniProt

Product Documents for Recombinant Human Octa-Ub/Ub8 WT Chains (K63-linked), CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Octa-Ub/Ub8 WT Chains (K63-linked), CF

For research use only

Loading...
Loading...